Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ALKS 9072 in Acute Exacerbation of Schizophrenia
2012-003445-15Phase 3Completed
- Sponsor
- Alkermes
- Start
- Nov 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing ALKS 9072 (aripiprazole lauroxil) with Placebo (2 arms). Primary endpoint: PANSS total score change from baseline to Day 85. Started Nov 2012; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2012-003445-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003445-15.